R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial
R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial
Assess the combination of efficacy of the combination of rituximab, bendamustine,
 mitoxantrone, dexamethasone in the treatment of patients with Follicular Lymphoma.
Assess the combination of efficacy and safety of the combination of rituximab, bendamustine,
 mitoxantrone, dexamethasone in the treatment of patients with Follicular Lymphoma who are
 refractory or in relapse.
Inclusion Criteria:

 1. Age ≥ 18 and ≤ 75 years.

 2. Patients with follicular lymphoma grade 1, 2 or 3a, CD20 +, histologically confirmed
 lymph node biopsy or tissue. Be accepted diagnosis in bone marrow if no accessible
 lymph nodes and whether it has discarded the mantle LLC, and NHL.

 3. Follicular lymphoma patients treated with the combination of rituximab and
 chemotherapy in first line, which have been refractory or relapsed after having
 achieved any responses to this first line of pretreatment (excluding radiotherapy).

 4. ECOG ≤ 2.

 5. Signed written informed consent.

 Exclusion Criteria:

 1. Clinical suspicion or documentation of histological transformation.

 2. Have received prior chemotherapy scheme, first line without Rituximab.

 3. Prior autologous or allogeneic.

 4. CNS infiltration by LF (primary CNS lymphoma or lymphomatous meningitis).

 5. Past or active Hepatitis B (at least one of the following markers HBsAg, HBe Ag,
 anti-HBc, HBV DNA)

 6. HCV infection. HIV infection or other conditions of serious immunosuppression.

 7. Previous neoplasms except non-melanoma skin cancer of the cervix or adequately
 treated.

 8. Cardiac function in cardiac patient known or prior treatment with anthracyclines with
 EF <50%.

 9. Impaired renal function (creatinine> 1.5 x Upper Limit of Normal, LSN) or a creatinine
 clearance <50 ml / h, not related to lymphoma.

 10. Impaired liver function (bilirubin, AST / ALT or GGT> 2 x ULN) were not related to
 lymphoma.

 11. Women who are nursing or pregnant. Women of childbearing potential will be included
 prior pregnancy test serum / urine negative. Use effective contraception to be kept
 for 1 year after cessation of rituximab.

 12. Patients with heart disease, pulmonary, neurological, psychiatric or severe metabolic
 and not secondary to lymphoma.

 13. Severe acute or chronic infection in activity.

 14. Any other concurrent medical or psychological comorbidity that might interfere with
 participation in this study.